Advertisement

Annals of Surgical Oncology

, Volume 20, Issue 9, pp 3015–3022 | Cite as

EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases

  • Jae Seok Lee
  • Hye Ryun Kim
  • Chang Young Lee
  • Mihwa Shin
  • Hyo Sup ShimEmail author
Thoracic Oncology

Abstract

Background

Gene amplifications are implicated in cancer development and progression. In this study we investigated the clinicopathologic characteristics associated with EGFR or TTF-1 amplification in lung adenocarcinomas and its prognostic significance.

Methods

We analyzed 118 cases of surgically resected primary lung adenocarcinomas. Amplification of the EGFR or TTF-1 gene was evaluated by fluorescence in situ hybridization and correlated with patients’ clinicopathologic features, including disease-free survival (DFS) and overall survival (OS), in all patients and a subset that were TTF-1 positive or had EGFR mutation. Progression-free survival (PFS) also was analyzed among patients with EGFR mutation who had recurred cancer that was treated with EGFR tyrosine kinase inhibitors.

Results

EGFR or TTF-1 gene amplification was an independent poor prognostic factor for DFS in all patients (p = 0.001), in patients with TTF-1 positivity (p = 0.010), and in patients with EGFR mutation (p < 0.001) and for OS in patients with TTF-1 positivity (p = 0.021) and patients with EGFR mutation (p < 0.001). Patients with TTF-1 amplification had a shorter PFS following EGFR TKI treatment (p = 0.040).

Conclusions

EGFR or TTF-1 gene amplification was a predictive factor for poor prognosis in terms of DFS and OS, especially in patients with TTF-1 positivity or EGFR mutation. Our results also suggested that TTF-1 amplification might be a predictive marker of poor response to EGFR-TKI therapy in patients with recurrent tumor after surgical resection.

Keywords

Overall Survival Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Mutation Anaplastic Lymphoma Kinase Bacterial Artificial Chromosome Clone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2011-0014077).

Supplementary material

10434_2013_2937_MOESM1_ESM.doc (1.5 mb)
Supplementary material 1 (DOC 1544 kb)

References

  1. 1.
    Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol. 2010;28:5219–28.PubMedCrossRefGoogle Scholar
  2. 2.
    Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012;136:504–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer—is it becoming a reality? Nat Rev Clin Oncol. 2010;7:401–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010;29:23–36.PubMedCrossRefGoogle Scholar
  5. 5.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.PubMedCrossRefGoogle Scholar
  6. 6.
    Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450:893–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B, et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA. 2007;104:16663–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008;68:2106–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012;21:348–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011;473:101–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009;13:1977–86.PubMedCrossRefGoogle Scholar
  12. 12.
    Li X, Wan L, Shen H, Geng J, Nie J, Wang G, et al. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol. 2012;7:76–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011;17:2434–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85.PubMedCrossRefGoogle Scholar
  15. 15.
    Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.PubMedCrossRefGoogle Scholar
  16. 16.
    Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol. 2009;217:65–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.Google Scholar
  19. 19.
    Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4:120ra17.Google Scholar
  20. 20.
    Albertson DG. Gene amplification in cancer. Trends Genet. 2006;22:447–55.PubMedCrossRefGoogle Scholar
  21. 21.
    Hirsch FR, Varella-Garcia M, Bunn PA, Jr., Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–807.PubMedCrossRefGoogle Scholar
  22. 22.
    Sasaki H, Shimizu S, Okuda K, Kawano O, Yukiue H, Yano M, et al. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer. 2009;64:295–300.PubMedCrossRefGoogle Scholar
  23. 23.
    Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE. 2009;4:e7464.PubMedCrossRefGoogle Scholar
  24. 24.
    Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond). 2009;116:27–35.CrossRefGoogle Scholar
  26. 26.
    Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, et al. Thyroid transcription factor 1–a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006;17:1673–6.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Jae Seok Lee
    • 1
  • Hye Ryun Kim
    • 2
  • Chang Young Lee
    • 3
  • Mihwa Shin
    • 1
  • Hyo Sup Shim
    • 1
    Email author
  1. 1.Department of PathologyYonsei University College of MedicineSeoulKorea
  2. 2.Division of Oncology, Department of Internal MedicineYonsei Cancer Center, Yonsei University College of MedicineSeoulKorea
  3. 3.Department of Thoracic and Cardiovascular SurgeryYonsei University College of MedicineSeoulKorea

Personalised recommendations